Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.41 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.41 |
| ▸ | PAK3 | O75914 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041675 | 0.74 | WEE1 (0.52) | WEE1FGFR1EGFRPAK1PAK4 | |
| SCHEMBL14682062 | 0.74 | PAK1 (0.49) | WEE1PAK1PAK4PKN1PAK2 | |
| SCHEMBL15036052 | 0.73 | WEE1 (0.51) | WEE1FGFR1EGFRPAK1PAK4 | |
| SCHEMBL15041860 | 0.72 | TNK2 (0.39) | FGFR1SRCTNK2 | |
| SCHEMBL15041532 | 0.72 | TNK2 (0.43) | WEE1PAK1PAK4PKN1PAK2 | |
| SCHEMBL13553662 | 0.72 | PKN1 (0.47) | WEE1FGFR1EGFRPAK1PAK4 | |
| SCHEMBL15041272 | 0.72 | PKN1 (0.47) | WEE1FGFR1EGFRPAK1PAK4 | |
| SCHEMBL13553814 | 0.72 | PKN1 (0.42) | FGFR1PAK1PAK4PKN1PAK2 | |
| SCHEMBL15041859 | 0.71 | CAMK2D (0.44) | WEE1PAK1PAK4PKN1PAK2 | |
| SCHEMBL15036372 | 0.71 | CDK4 (0.42) | FGFR1PDGFRBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | WEE1 1354/4885FGFR1 1720/4885EGFR 2713/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885FGFR1 1919/4885EGFR 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.